Edward N. and Della L. Thome Memorial Foundation Awards Program in Alzheimer’s Disease Drug Discovery Research

The COVID-19 pandemic continues to evolve and impact our personal and professional lives. We want to assure our trustees, reviewers, and grantee communities that our TMF staff continues to provide high quality biomedical research grantmaking services. We will do our part to help manage any potential challenges and continue supporting research to the extent that it is possible. Please notify us with any questions or requests.

 

SUPPORTING INNOVATIVE DRUG DISCOVERY RESEARCH IN ALZHEIMER’S DISEASE

The goal of the Thome Memorial Foundation Awards Program in Alzheimer’s Disease Drug Discovery Research is to support innovative drug discovery research that will lead to improved therapies for individuals suffering from Alzheimer’s disease.

Researchers dedicated to the validation and testing of target compounds and therapeutic agents including biologics and small molecules, are encouraged to apply. Consideration will be given to research focused on pathogenic mechanisms including inflammatory response, synaptic toxicity, neuronal toxicity, and endosomal/lysosomal trafficking defects.

Basic research or new target discovery, genetic studies, biomarker research, neuro-imaging and clinical studies are currently outside the scope of this Program.

All applicants must hold a faculty appointment at a non-profit academic, medical, non-governmental or research institution in the United States. US citizenship is not required. Applicants do not need to be nominated by their institutions. Preference will be given to originality of ideas, regardless of faculty seniority.

For complete Eligibility Requirements and Application Instructions, download the Guidelines available to the right.